1
|
Held M, Kozmar A, Sestan M, Turudic D, Kifer N, Srsen S, Gagro A, Frkovic M, Jelusic M. Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV). Int J Mol Sci 2024; 25:4383. [PMID: 38673968 PMCID: PMC11050592 DOI: 10.3390/ijms25084383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Revised: 04/11/2024] [Accepted: 04/13/2024] [Indexed: 04/28/2024] Open
Abstract
The pathogenesis of IgAV, the most common systemic vasculitis in childhood, appears to be complex and requires further elucidation. We aimed to investigate the potential role of galactose-deficient immunoglobulin A1 (Gd-IgA1), high-mobility group box 1 (HMGB1), receptor for advanced glycation end products (RAGE) and protocadherin 1 (PCDH1) in the pathogenesis of IgAV. Our prospective study enrolled 86 patients with IgAV and 70 controls. HMGB1, RAGE, Gd-IgA1 and PCDH1 in serum and urine were determined by the enzyme-linked immunosorbent assay (ELISA) method at the onset of the disease and after a six-month interval in patients and once in the control group. Serum concentrations of HMGB1, RAGE and PCDH1 and urinary concentrations of HMGB1, RAGE, Gd-IgA1 and PCDH1 were significantly higher in patients with IgAV than in the control group (p < 0.001). Concentrations of HMGB1 (5573 pg/mL vs. 3477 pg/mL vs. 1088 pg/mL, p < 0.001) and RAGE (309 pg/mL vs. 302.4 pg/mL vs. 201.3 pg/mL, p = 0.012) in the serum of patients remained significantly elevated when the disease onset was compared with the six-month follow-up interval, and thus could be a potential marker of disease activity. Urinary concentration of HMGB1 measured in the follow-up period was higher in patients with nephritis compared to IgAV without nephritis (270.9 (146.7-542.7) ng/mmol vs. 133.2 (85.9-318.6) ng/mmol, p = 0.049) and significantly positively correlated with the urine albumine to creatinine ratio (τ = 0.184, p < 0.05), the number of erythrocytes in urine samples (τ = 0.193, p < 0.05) and with the outcome of nephritis (τ = 0.287, p < 0.05); therefore, HMGB1 could be a potential tool for monitoring patients with IgAV who develop nephritis. Taken together, our results imply a possible interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in the development of IgAV. The identification of sensitive biomarkers in IgAV may provide disease prevention and future therapeutics.
Collapse
Affiliation(s)
- Martina Held
- Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; (M.H.); (M.S.); (D.T.); (N.K.); (M.F.)
| | - Ana Kozmar
- Department of Laboratory Diagnostics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia;
| | - Mario Sestan
- Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; (M.H.); (M.S.); (D.T.); (N.K.); (M.F.)
| | - Daniel Turudic
- Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; (M.H.); (M.S.); (D.T.); (N.K.); (M.F.)
| | - Nastasia Kifer
- Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; (M.H.); (M.S.); (D.T.); (N.K.); (M.F.)
| | - Sasa Srsen
- Department of Pediatrics, University of Split School of Medicine, University Hospital Centre Split, 21000 Split, Croatia;
| | - Alenka Gagro
- Children’s Hospital Zagreb, Medical Faculty Osijek, Josip Juraj Strossmayer University of Osijek, 10000 Zagreb, Croatia;
| | - Marijan Frkovic
- Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; (M.H.); (M.S.); (D.T.); (N.K.); (M.F.)
| | - Marija Jelusic
- Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; (M.H.); (M.S.); (D.T.); (N.K.); (M.F.)
| |
Collapse
|
2
|
Held M, Stingl Jankovic K, Sestan M, Sapina M, Kifer N, Srsen S, Frkovic M, Gagro A, Grubic Z, Jelusic M. HLA Polymorphisms and Clinical Manifestations in IgA Vasculitis. Int J Mol Sci 2024; 25:882. [PMID: 38255953 PMCID: PMC10815612 DOI: 10.3390/ijms25020882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Revised: 12/22/2023] [Accepted: 01/09/2024] [Indexed: 01/24/2024] Open
Abstract
Studies concerning the genetic background of IgA vasculitis (IgAV), a small-vessel vasculitis occurring predominantly in childhood, have confirmed that the HLA-DRB1 gene showed a strong association with disease susceptibility. The objective was to investigate human leukocyte antigen (HLA) polymorphisms among Croatian patients with IgAV and their influence on disease susceptibility and clinical heterogeneity. Thus, 130 children with IgAV and 202 unrelated healthy individuals were enrolled in the study. Genomic DNA was extracted from whole peripheral blood, and HLA-A, -B, -DRB1 and -DQB1 gene polymorphism analysis was performed. HLA-A*03 (21.4% vs. 12.38%, p = 0.0092), HLA-B*37 (2.9% vs. 0.2%, p = 0.0054) and HLA-DRB1*12 (3.1% vs. 0.7%, p = 0.0216) alleles were significantly more frequent in IgAV patients than in controls. High-resolution typing revealed significantly higher frequency of HLA-DRB1*10:01 and -DRB1*11:03 among IgAV patients with gastrointestinal manifestations of the disease in comparison to controls (p = 0.0021 and p = 0.0301, respectively), while HLA-DRB1*14:01P occurred significantly more often in the group of patients who developed nephritis during the course of the disease (17.5% vs. 4.5%, p = 0.0006). Our results demonstrated that there is an association of HLA-A*03, HLA-B*37 and HLA-DRB1*12 alleles with susceptibility to IgAV in the examined Croatian pediatric population. Studies which aim to determine the HLA profile may contribute to the elucidation of the genetic background of autoimmune diseases, including IgAV.
Collapse
Affiliation(s)
- Martina Held
- Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, 10000 Zagreb, Croatia; (M.H.)
| | - Katarina Stingl Jankovic
- Tissue Typing Centre, Clinical Department for Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia (Z.G.)
| | - Mario Sestan
- Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, 10000 Zagreb, Croatia; (M.H.)
| | - Matej Sapina
- Department of Pediatrics, University Hospital Centre Osijek, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, 31000 Osijek, Croatia;
| | - Nastasia Kifer
- Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, 10000 Zagreb, Croatia; (M.H.)
| | - Sasa Srsen
- Department of Pediatrics, University of Split School of Medicine, University Hospital Centre Split, 21000 Split, Croatia;
| | - Marijan Frkovic
- Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, 10000 Zagreb, Croatia; (M.H.)
| | - Alenka Gagro
- Children’s Hospital Zagreb, Medical Faculty Osijek, Josip Juraj Strossmayer University of Osijek, 10000 Zagreb, Croatia;
| | - Zorana Grubic
- Tissue Typing Centre, Clinical Department for Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia (Z.G.)
| | - Marija Jelusic
- Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, 10000 Zagreb, Croatia; (M.H.)
| |
Collapse
|
3
|
Deniz R, Güner N, Ekmen ŞA, Mutlu IN, Özgür DS, Karaalioğlu B, Akkuzu G, Yıldırım F, Kalkan K, Güzelant-Özköse G, İnce B, Erdoğan M, Özlük Y, Kılıçaslan I, Bes C. Discrepancies between clinical and pathological findings seen at renal biopsy in rheumatological diseases. Reumatismo 2023; 75. [PMID: 37721346 DOI: 10.4081/reumatismo.2023.1586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Accepted: 07/04/2023] [Indexed: 09/19/2023] Open
Abstract
OBJECTIVE Renal biopsy contributes to the diagnosis, follow-up, and treatment of many rheumatic conditions. This study assessed the diagnostic role and safety of renal biopsies in a tertiary rheumatology clinic. METHODS Renal biopsies performed between June 2020 and December 2022 were screened, and demographic, clinical, histopathological, and safety data were collected from patient records. RESULTS In this study, 33 males and 38 females were included. Except for 1 patient who received acetylsalicylic acid, antiaggregant, and/or anticoagulant drugs were stopped before the biopsy. Complications included a decrease of hemoglobin in 8 patients (11.3%) and microscopic hematuria in 40 patients (56.3%). Control ultrasonography was performed in 16 patients (22.5%), and a self-limiting hematoma was found in 4 of them (5.6%) without additional complications. While less than 10 glomeruli were obtained in 9 patients (9.9%), diagnosis success was 94.4%. Histopathological data were consistent with one of the pre-biopsy diagnoses in 54 of 67 cases (80.6%) but showed discrepancies in 19.4% (n=13) of patients. A repeat biopsy was performed in 7 patients for re-staging or insufficient biopsy. CONCLUSIONS Renal biopsy significantly contributes to rheumatology practice, especially in patients with complex clinical and laboratory findings or in whom different treatments can be given according to the presence, severity, and type of renal involvement. Although the possibility of obtaining insufficient tissue and the need for re-staging and repeat biopsy in the follow-up might be expected, complication risk does not seem to be a big concern. Renal biopsy often evidenced discrepancies between pre-biopsy diagnosis and histopathological findings.
Collapse
Affiliation(s)
- R Deniz
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - N Güner
- Department of Internal Medicine, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - Ş A Ekmen
- Department of Internal Medicine, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - I N Mutlu
- Department of Radiology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - D S Özgür
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - B Karaalioğlu
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - G Akkuzu
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - F Yıldırım
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - K Kalkan
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - G Güzelant-Özköse
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - B İnce
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - M Erdoğan
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| | - Y Özlük
- Department of Pathology, Faculty of Medicine, University of İstanbul.
| | - I Kılıçaslan
- Department of Pathology, Faculty of Medicine, University of İstanbul.
| | - C Bes
- Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, İstanbul.
| |
Collapse
|